 |
|
|
 |
|
Rationale:
- Surgery produces long-term weight loss that can be more than 25% of body weight in 1 year.
- Lost weight tends to be regained only slowly, if at all.
- Surgery improves quality of life.
|
|
Evidence:
- A prospective controlled study (350) and a retrospective chart study (351) showed that bariatric surgery reduces mortality by 30% to 54% with 7 to 10.9 years follow-up.
- Surgery may be recommended to individuals with progressive obesity, a BMI >40 kg/m2, or a BMI >35 kg/m2 with comorbidities (472).
- For individuals with sleep apnea, bariatric surgery may be beneficial (339; 473).
- Surgical therapy reduces body weight by 20% to 35% (339).
- Gastric bypass procedures generally produce more maintainable weight loss than gastroplasty or gastric banding (277), a finding supported by a systematic review (474).
- The Swedish adjustable band and the Lap-Band produce comparable weight losses in a randomized trial (475).
- Weight loss through surgery or other means reduces risks to health, including hypertension and diabetes (277; 339; 352; 353; 476; 477; 478).
- Weight loss by surgery improves social functioning (278; 477).
- A 2-year, randomized, controlled trial in 80 people with a BMI between 30 and 35 kg/m2 showed a 21.6% weight loss in the laparoscopic adjustable gastric band group compared to 5.5% in the control group (479). Intraoperative use of dexmedetomidine, an α2-agonist, decreased pentanyl and anti-emetic therapy, and shortened length of stay in the postanesthesia care unit (480).
- A meta-analysis showed that risk of gallstones after bariatric surgery was reduced from 27.7% to 8.8% with ursodeoxycholic
acid (481).
- A propylene mesh used in wound closure significantly lowered postoperative hernia (482).
- Intragastric balloons in a meta-analysis of 15 studies produced a 12.2% (14.7 kg) weight loss; complications were mild and
4.2% required early removal (483).
- Surgical weight loss lengthens life by reducing mortality (350; 351).
|
|
Comments:
|
| FAQs |
|
|
|
George A. Bray, MD, is a speaker for Eli Lilly, Amylin Corp., and Merck & Co., received grants from Merck & Co., and Takeda Pharmaceuticals; and
has consulted for Sanofi-Aventis, Merck, and Amylin. Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|